# Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Source: https://onco.cc/trials/nct06690840/  
OnCo record `nct06690840` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of atezolizumab, cyclophosphamide and vinorelbine in triple-negative breast cancer, run by European Institute of Oncology, now recruiting.

## Summary

Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients is a phase 2, interventional study registered as NCT06690840 by European Institute of Oncology, with a registry enrolment figure of 45 participants, started 2025-03-06 and due to reach its primary completion in 2026-12-15. Interventions recorded: Atezolizumab in combination with Cyclophosphamide and Vinorelbine. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Patients with locally advanced or metastatic, histologically documented TNBC (absence of human epidermal growth factor 2 \[HER2\], estrogen receptor \[ER\], and progesterone receptor \[PR\] expression) PD-L1+ (Immune Cell \>1% using Ventana SP142 assay), not amenable to surgical therapy". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: AZALEA
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06690840
- Phase: 2
- Setting: A Phase II Study of Atezolizumab, Vinorelbine and Weekly Cyclophosphamide as T-cell Activators in First Line Metastatic Triple Negative Breast Cancer Patients Pre-treated With Anti-PD-L1/PD-1
- Sponsor: European Institute of Oncology
- Enrolled: 45

## Sources

- ClinicalTrials.gov NCT06690840: https://clinicaltrials.gov/study/NCT06690840

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06690840.json